pharmaphorum

SEPTEMBER 29, 2022

Kyle helps companies build and refine corporate compliance programs, including advising clients on regulatory and compliance matters involving the Food, Drug and Cosmetic Act, the False Claims Act, the Anti-Kickback Statute, the AdvaMed Code and the PhRMA Code.

Development 104

Development Regulation Production Life Science 104

Drug Discovery World

JANUARY 30, 2024

High-cost materials: Specialised equipment, reagents, and cell culture media significantly contribute to the overall cost. Intellectual property: High patent royalties and licensing fees for key technologies can inflate treatment costs. Automating and scaling up manufacturing is crucial for cost reduction.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

FDA Law Blog

AUGUST 3, 2022

If anything, the announcement was remarkably inconspicuous: a seemingly throwaway sentence in a draft compliance policy guide for research use only and investigational use only products. There was no fanfare for this momentous “birth.” At the same time, FDA’s basic operational stance hasn’t changed much either.

In-Vitro 98

In-Vitro Regulation Compliance Production 98

FDA Law Blog

NOVEMBER 1, 2023

The PR first sets out to establish that it has authority to regulate in vitro diagnostic “test systems” as devices, and not just the system’s individual components, such as reagents, instruments, specimen collection devices, and software. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Regulation 81

Regulation In-Vitro Manufacturing Licensing 81

The Pharma Data

DECEMBER 23, 2020

based Avacta Group entered into a license agreement with Astrea Bioseparations that allows that company to use Avacta’s Affimer platform in affinity purification applications. The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation.

Drugs 52

Drugs Licensing Licensing Vaccination 52